News About Expanesthetics

Expanesthetics Explores Developing Market Strategy at WCA in Hong Kong

August 31, 2016

Expanesthetics' CEO, Mark Holman, and COO, Shane Austin attended the 16th World Congress of Anaesthesiologists in Hong Kong this month to meet with a who's who of industry leaders interested in the development of new inhalation anesthetics for developing markets - regions that have traditionally been late adopters of new pharmaceutical products. Because a new inhalation anesthetic has not been developed in decades, the discovery that forms the heart of Expanesthetics' technology is an opportunity for the leaders in these markets to bring new and better inhalation anesthetics to these parts of the world. Expanesthetics' team capitalized on its visit to the "Pearl of the Orient" to meet with leaders from China, Japan, and Europe, among others, and laid the groundwork for far-reaching and mutually beneficial relationships.

Back to top

Expanesthetics Considers Office in Melbourne, Australia in Preparation for Clinical Trial Phase

August 12, 2016

This month, Expanesthetics' CEO, Mark Holman, and COO, Shane Austin, traveled to Melbourne, Australia to explore clinical resources and strengthen the company's network of relationships; all this to lay the groundwork for future first-in-human (FIH) clinical trials. Melbourne is a global hub of pharmaceutical clinical trials, and as the company's anesthetic and analgesic programs continue to advance, Expanesthetics is contemplating the launch of an "Asian-Pacific" office in Australia to take advantage of the vast network of resources that collaborators in that country have to offer, as well as the advantageous regulatory environment "down under." Productive meetings with Murdoch Children's Research Institute, the State Government of Victoria - Department of Economic Development and many others have given Expanesthetics many reasons to look favorably on Melbourne as the future site of such an expansion. Stay tuned for updates!

Back to top

Expanesthetics Hires Chief Scientific Officer, Dr. Peter Wright

July 1, 2016

Expanesthetics continues to expand its management team with the hiring this month of part-time Chief Scientific Officer Dr. Peter Wright. Dr. Wright has a PhD in Pharmacokinetics, is a former Professor of Anesthesia at the University of California, San Francisco and has been practicing anesthesia for over 25 years. He will be leading Expanesthetics' research efforts as both the anesthetic and analgesic programs continue to advance through preclinical studies. Please join us in welcoming Dr. Wright to the Expanesthetics family!

Back to top

Expanesthetics Crosses $1M Funding Milestone

February 7, 2016 | Davis Enterprise

The Davis Enterprise, Expanesthetics' home town newspaper, reported the achievement of an important fundraising milestone. In 2012, Mark Holman met Robert Brosnan at an entrepreneurship academy at the local university campus. Robert had come to learn about building new companies on a foundation of innovative technology and Mark was serving as a mentor to the many faculty members and students.

Back to top

Expanesthetics Spotlighted by Leading Research University

February 2, 2016 | Child Family Institute for Innovation and Entrepreneurship

Founded in 2012, Expanesthetics is tackling one of the longest-standing scientific questions in modern medicine: How do general anesthetics work? The company's goal is to expand the choice of anesthetic agents available for clinical use in order to improve patient outcomes and reduce costs. This story tells some of Expanesthetics' history and progress to-date.

Back to top